Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447898 | 1.00 | LMNA (0.41) | LMNAMGLLSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6448452 | 0.86 | EPHX1 (0.36) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL6448447 | 0.86 | EPHX1 (0.36) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL6448054 | 0.76 | NAAA (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6448059 | 0.76 | NAAA (0.39) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6447041 | 0.73 | ATM (0.47) | LMNASMN1; SMN2 | |
| SCHEMBL6447044 | 0.73 | ATM (0.47) | LMNASMN1; SMN2 | |
| SCHEMBL6448274 | 0.72 | EPHX1 (0.45) | MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL8895551 | 0.72 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL9132826 | 0.72 | LMNA (0.55) | LMNASLC1A3SLC1A2SLC1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921832-B2 | Optically active fluorine-containing compounds and processes for their production | TOSOH CORPORATION (JP) | 2005-07-26 | — | — | US | disclosed |
| US-20040147756-A1 | Optically active fluorine-containing compounds and processes for their production | TOSOH CORPORATION (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1422226-A1 | Optically active fluorine-containing compounds and processes for their production | Tosoh Corporation (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147756-A1 | Optically active fluorine-containing compounds and processes for their production | CYP2C19, CYP2F1, CYP2B6 | LMNA 3125/4885MGLL 3160/4885SLC1A3 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.